1,668.30
+3.89%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Tatva Chintan Pharma Chem
Its shares trade on NSE under the ticker TATVA.NS. It has been listed since 29 July 2021. In the fiscal year to 31 March 2026, it reported revenue of ₹5.06bn and net income of ₹420.5m. At that date it held total assets of ₹10.04bn and shareholders' equity of ₹7.82bn.
Tatva Chintan Pharma Chem Ltd. is a chemicals manufacturing company. The company is headquartered in Vadodara, Gujarat. The company went IPO on 2021-07-29. The firm is engaged in the manufacturing of verity of chemicals include structure directing agents (SDAs), phase transfer catalysts (PTCs), electrolyte salts for capacitor batteries, and pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC). Its SDAs are quarternary salts, which helps in the formation of channels and pores during the synthesis of zeolites. Its PTCs are used to facilitate the migration of a reactant from one phase into another phase where the reaction occurs in a heterogeneous multi-phase system. The firm operates two manufacturing facilities situated at Ankleshwar and Dahej in Bharuch, Gujarat, India. The firm is focused on serving various customers across various industries, including the automotive, petroleum, pharmaceutical, agro chemicals, paints and coatings, dyes and pigments, personal care and flavors and fragrances industries.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Materials
- Industry
- Chemicals
- Listed since
- 29 Jul 2021
- Employees
- 608
- Website
- tatvachintan.com ↗
Leadership
Pay as last reported
- Mr. Chintan ShahExecutive Chairman of the Board, Managing Director, since 1996₹17.1m
- Mr. Ajesh PillaiChief Financial Officer
- Mr. Ishwar NayiCompliance Officer, Company Secretary
- Mr. Ajaykumar PatelWhole Time Director, since 1996₹17.1m
- Mr. Shekhar SomaniWhole Time Director, since 1996₹17.1m
- Dr. Manher DesaiNon-Executive Independent Director₹210,000
- Mr. Subhash PatelNon-Executive Independent Director₹230,000
- Dr. Avani UmattNon-Executive Independent Director₹190,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 74
- Environment
- 54
- Social
- 99
- Governance
- 70
- Direct emissions (scope 1)
- 1,782.18 t
- Energy emissions (scope 2)
- 16,891.26 t
- Women in the workforce
- 2.61%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Tatva Chintan Pharma Chem Ltd. manufactures SDAs and PTCs for zeolite synthesis and multi-phase reactions.
- The company operates two manufacturing facilities in Ankleshwar and Dahej, Bharuch, Gujarat.
- Tatva Chintan serves automotive, pharmaceutical, and agrochemical industries with specialty chemicals.
Weaknesses
- The company has only two manufacturing facilities in Bharuch, Gujarat, limiting production scale.
- Tatva Chintan's focus on specialty chemicals may restrict market diversification.
- With 608 employees, the company has a relatively small workforce for chemical manufacturing scale.
Opportunities
- Growing demand for pharmaceutical intermediates in the Indian market presents expansion potential.
- Increasing use of electrolyte salts for capacitor batteries in electronics offers new markets.
- Expansion into international markets for PASC chemicals could boost revenue streams.
Threats
- Competition from established chemical manufacturers in Gujarat may impact market share.
- Fluctuations in raw material costs could affect profit margins significantly.
- Regulatory changes in the Indian chemical industry might increase operational costs.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.